Glioblastoma: synergy of growth promotion between CCL5 and NK‐1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti‐HIV drug and blocking NK‐1R with aprepitant, an FDA approved anti‐nausea drug